CTSO — Cytosorbents Corporation
$4.87
$-0.50 (-9.31%)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Market Cap
$15.35M
Forward P/E
Infinityx
52-Week Range
N/A
CTSO Price History
Revenue vs. Net Income
$37.1M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$12.9M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-17.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.3%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+14.3%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).